David P Schenkein Agios Pharmaceuticals, Inc. (AGIO) insider trading activity

David P Schenkein is Director of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 126,242 shares of AGIO, which is worth approximately $7.03 Million. The most recent transaction as insider was on Jun 13, 2024, when has been sold 3,388 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 126K

0% 3M change

2.76% 12M change

Total Value Held $7.03 Million

David P Schenkein Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 13 2024	BUY Exercise of conversion of derivative security	-	3,388 Added 2.61%	126,242 Common Stock
Feb 27 2024	SELL Open market or private sale	$2,373,824 $34.24 p/Share	69,329 Reduced 36.07%	122,854 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	$2,193,569 $31.64 p/Share	69,329 Added 27.77%	180,325 Common Stock
Feb 26 2024	SELL Open market or private sale	$677,441 $33.19 p/Share	20,411 Reduced 14.25%	122,854 Common Stock
Feb 26 2024	BUY Exercise of conversion of derivative security	$645,804 $31.64 p/Share	20,411 Added 12.47%	143,265 Common Stock
Feb 23 2024	SELL Open market or private sale	$1,577,509 $33.05 p/Share	47,731 Reduced 27.98%	122,854 Common Stock
Feb 23 2024	BUY Exercise of conversion of derivative security	$1,510,208 $31.64 p/Share	47,731 Added 21.86%	170,585 Common Stock
Jun 21 2023	BUY Exercise of conversion of derivative security	-	4,975 Added 3.89%	122,854 Common Stock
Apr 03 2023	SELL Open market or private sale	$373,894 $22.85 p/Share	16,363 Reduced 12.19%	117,879 Common Stock
Apr 03 2023	BUY Exercise of conversion of derivative security	$148,085 $9.05 p/Share	16,363 Added 10.86%	134,242 Common Stock
Mar 27 2023	SELL Open market or private sale	$443,000 $22.15 p/Share	20,000 Reduced 14.51%	117,879 Common Stock
Mar 27 2023	BUY Exercise of conversion of derivative security	$181,000 $9.05 p/Share	20,000 Added 12.67%	137,879 Common Stock
Mar 13 2023	SELL Open market or private sale	$451,800 $22.59 p/Share	20,000 Reduced 14.51%	117,879 Common Stock
Mar 13 2023	BUY Exercise of conversion of derivative security	$181,000 $9.05 p/Share	20,000 Added 12.67%	137,879 Common Stock
Feb 27 2023	SELL Open market or private sale	$507,400 $25.37 p/Share	20,000 Reduced 14.51%	117,879 Common Stock
Feb 27 2023	BUY Exercise of conversion of derivative security	$181,000 $9.05 p/Share	20,000 Added 12.67%	137,879 Common Stock
Feb 13 2023	SELL Open market or private sale	$572,400 $28.62 p/Share	20,000 Reduced 14.51%	117,879 Common Stock
Feb 13 2023	BUY Exercise of conversion of derivative security	$181,000 $9.05 p/Share	20,000 Added 12.67%	137,879 Common Stock
Jan 30 2023	SELL Open market or private sale	$591,000 $29.55 p/Share	20,000 Reduced 14.51%	117,879 Common Stock
Jan 30 2023	BUY Exercise of conversion of derivative security	$181,000 $9.05 p/Share	20,000 Added 12.67%	137,879 Common Stock
Jan 17 2023	SELL Open market or private sale	$583,200 $29.16 p/Share	20,000 Reduced 14.51%	117,879 Common Stock
Jan 17 2023	BUY Exercise of conversion of derivative security	$181,000 $9.05 p/Share	20,000 Added 12.67%	137,879 Common Stock
May 20 2022	BUY Exercise of conversion of derivative security	-	1,585 Added 1.33%	117,879 Common Stock
Feb 22 2022	SELL Payment of exercise price or tax liability	$22,043 $29.08 p/Share	758 Reduced 0.65%	116,294 Common Stock
Feb 22 2022	BUY Exercise of conversion of derivative security	-	2,775 Added 2.32%	117,052 Common Stock

Also insider at

REGN

REGENERON PHARMACEUTICALS, INC. Healthcare

Director

DNLI

Denali Therapeutics Inc. Healthcare

Director

PRME

Prime Medicine, Inc.

Director

DPS